Research graph
References from Research on the innovation of medical expenses protection mechanism for rare disease patients in China. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2014 · External reference
Unresolved reference
2019 · External reference
Unresolved reference
2021 · External reference
Is sub-national healthcare social protection sufficient for protecting rare disease patients? The case of China
10.3389/fpubh.2023.1198368 · 2023 · External reference
A research on the development model of "city-customized medical insurance"
10.13497/j.cnki.is.2022.01.001 · 2022 · External reference
Exploring the path for patient organizations to participate in medical security for rare diseases
10.3389/fpubh.2025.1484286 · 2025 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2016 · External reference
Analysis of incentive policies and initiatives on orphan drug development in China: challenges, reforms and implications
10.1186/s13023-023-02684-8 · 2023 · External reference
Orphan drug policy analysis in China
10.3389/fphar.2024.1278710 · 2024 · External reference
Sustainable rare diseases business and drug access: no time for misconceptions
10.1186/1750-1172-8-109 · 2013 · External reference
Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives
10.1186/1750-1172-9-20 · 2014 · External reference
Bridging the new drug access gap between China and the United States and its related policies
10.3389/fphar.2023.1296737 · 2024 · External reference
Access and use of WHO essential medicines in Italy
10.3389/fpubh.2023.1211208 · 2023 · External reference
Overview of clinical pharmacology packages of new drug applications approved for the treatment of rare diseases
10.1002/jcph.2167 · 2022 · External reference
Network established to collaborate on diagnosis and treatment of rare diseases in China: a strategic alliance backed by tiered healthcare is the key to the future
10.5582/irdr.2019.01024 · 2019 · External reference
Current situation and prospect for the diagnosis and treatment of pediatric critical rare diseases in China
10.1002/ped4.12419 · 2024 · External reference
Quantifying hope: an EU perspective of rare disease therapeutic space and market dynamics
10.3389/fpubh.2025.1520467 · 2025 · External reference
An analysis of medical care services for children with rare diseases in the Russian Federation
10.3389/fphar.2021.754073 · 2021 · External reference
Overview on social security system of rare diseases in China
10.5582/bst.2019.01209 · 2019 · External reference
Utilization and affordability of health insurance coverage for rare disease drugs in a first-tier city in Northeast China from 2018 to 2021: a study based on the health insurance claims database
10.1186/s12939-024-02225-0 · 2024 · External reference
Sustainable reimbursement of the B-centres for rare diseases in Germany-status quo and solution approaches
10.1007/s00103-022-03562-7 · 2022 · External reference
Rare diseases and orphan drugs in Japan: developing multiple strategies of regulation and research
10.1517/21678707.2013.832201 · 2013 · External reference
Welfare pluralism: welfare provision transformation from state to multi-sectors
2006 · External reference
Unresolved reference
External reference
Unresolved reference
2018 · External reference
Unresolved reference
2023 · External reference
Spectrum and epidemiology of rare diseases in a Chinese natural population of 14.31 million residents, 2012–2023
10.1186/s13023-025-03933-8 · 2025 · External reference
National Rare Diseases Registry System (NRDRS): China’s first nation-wide rare diseases demographic analyses
10.1186/s13023-021-02130-7 · 2021 · External reference
Using thematic analysis in psychology
10.1191/1478088706qp063oa · 2006 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2025 · External reference
A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries
10.3389/fpubh.2019.00416 · 2020 · External reference
Unresolved reference
2026 · External reference
US health care reform and transplantation. Part I: overview and impact on access and reimbursement in the private sector
10.1111/j.1600-6143.2010.03246.x · 2010 · External reference
Health care reform advances in 2024: plans to release the first edition of the category C pharmaceutical catalog within the year
2025 · External reference
Unresolved reference
External reference
Rare diseases in Chile: challenges and recommendations in universal health coverage context
10.1186/s13023-019-1261-8 · 2019 · External reference
Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries
10.1371/journal.pone.0140002 · 2015 · External reference
The role of patient organizations in shaping research, health policies, and health Services for Rare Genetic Diseases: the Dutch experience
10.3390/genes15091162 · 2024 · External reference
